Your browser doesn't support javascript.
loading
Clinical Observation of Milrinone Injection in the Treatment of Hypertensive Heart Disease Complicated with Heart Failure / 中国药房
China Pharmacy ; (12): 677-679,680, 2017.
Article Dans Chinois | WPRIM | ID: wpr-606395
ABSTRACT

OBJECTIVE:

To observe therapeutic efficacy and safety of Milrinone injection in the treatment of hypertensive heart disease complicated with heart failure.

METHODS:

A total of 120 patients with hypertensive heart disease complicated with chronic heart failure were randomized into control group and observation group according to random number table,with 60 cases in each group. Control group received routine therapy,including blood pressure controlling,anti-heart failure and other symptomatic treatment;observation group was additionally given Milrinone injection 0.3 mg/kg,continuous pump,qd. A treatment course lasted for 5 d. Both groups received one course of treatment each month for consecutive 6 months. Both groups were followed up for one year. 6 min walking distance(6MWD),BNP,LVEF,CI,LVEDD,heart rate,sitting systolic blood pressure(SiSBP)and sitting diastolic blood pressure(SiDBP),re-hospitalization rate and cardiovascular mortality were observed in 2 groups before treatment, after 3,6 months and 1 year of treatment;therapeutic efficacy of heart function and the incidence of ADR were compared between 2 groups.

RESULTS:

Before treatment,there was no statistical significance in 6MWD,BNP,LVEF,CI,heart rate,SiSBP and SiDBP between 2 groups;after 3 months,6 months and 1 year of treatment,6MWD,LVEF and CI of 2 groups were increased significantly,while BNP,LVEDD,resting heart rate,SiSBP and SiDBP were decreased significantly;the observation group was significantly better than the control group,with statistical significance(P0.05). There were no statistical signifi-cance in the incidence of ADR between 2 groups (P>0.05).

CONCLUSIONS:

Milrinone injection shows good efficacy in the treatment of hypertensive heart disease complicated with heart failure,can significantly reduce BNP and re-hospitalization rate as well as improve prognosis with good safety.

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Type d'étude: Essai clinique contrôlé langue: Chinois Texte intégral: China Pharmacy Année: 2017 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Type d'étude: Essai clinique contrôlé langue: Chinois Texte intégral: China Pharmacy Année: 2017 Type: Article